Wy. Hu et al., EFFECT OF CHRONIC CAPTOPRIL TREATMENT ON CIRCULATING AND TISSUE RENIN-ANGIOTENSIN SYSTEM IN SHR RATS, Zhongguo yaoli xuebao, 17(6), 1996, pp. 507-512
AIM: To study the effect of captopril treatment and its withdrawal on
the circulating and tissue peptidyl-dipeptidase A, angiotensinogen (AG
T), and angiotensin II (A II), in relation to left ventricular hypertr
ophy (LVH) and systolic blood pressure (SEP). METHODS: SHR male rats w
ere given captopril 100 mg . kg(-1). d(-1) [SHR(cap), number (n) = 43]
orally in mixture with milk powder as vehicle from intrautero period
to 16 wk of age. Rats were killed at 16 (n = 19) and 40 (n = 24) wk of
age, respectively. Male, age-matched untreated SHR and WKY rats serve
d as controls. SEP, left ventricular mass/body weight (LVM/BW) ratio,
left ventricular (LV) myocardium and plasma A II concentration, aortic
and serum peptidyl-dipeptidase A activity, AGT mRNA level in kidney a
nd liver, renal renin mRNA level were determined. RESULTS: Captopril t
reatment decreased SEP and reduced LVM/BW at 16 and 40 wk of age, and
persistently inhibited LV myocardium A II, aortic peptidyl-dipeptidase
A activity, and AGT gene expression in kidney even after the treatmen
t was removed. Nevertheless, no changes were found in plasma A II conc
entration, serum peptidyl-dipeptidase A activity, and AGT mRNA level i
n liver by captopril therapy. Renal renin mRNA level was low in SHR an
d WKY rats, but it was increased by captopril treatment. Tissue renin-
angiotensin system (RAS) such as AGT mRNA in kidney, aortic peptidyl-d
ipeptidase A activity, and LV myocardium A II, rather than circulating
RAS (AGT mRNA in liver, renin mRNA in kidney, serum peptidyl-dipeptid
ase A activity and plasma A II), were persistently inhibited by early
captopril treatment, even after the withdrawal of the treatment. CONCL
USION: The long-term inhibition of tissue RAS is one of the mechanisms
of the persistent hypotensive effect of captopril treatment.